Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBITDA (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EBITDA for 17 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 35.33% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$496.1 million through Dec 2025, down 99325.65% year-over-year, with the annual reading at -$493.4 million for FY2025, 1836.55% down from the prior year.
  • EBITDA hit $23.0 million in Q4 2025 for Integra Lifesciences Holdings, up from -$6.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $75.8 million in Q1 2021 to a low of -$490.9 million in Q2 2025.
  • Historically, EBITDA has averaged $1.1 million across 5 years, with a median of $25.9 million in 2021.
  • Biggest five-year swings in EBITDA: surged 2523.84% in 2021 and later tumbled 2296.61% in 2025.
  • Year by year, EBITDA stood at $58.2 million in 2021, then increased by 16.52% to $67.8 million in 2022, then crashed by 46.86% to $36.0 million in 2023, then dropped by 1.17% to $35.6 million in 2024, then crashed by 35.33% to $23.0 million in 2025.
  • Business Quant data shows EBITDA for IART at $23.0 million in Q4 2025, -$6.5 million in Q3 2025, and -$490.9 million in Q2 2025.